Abstract
Targeted therapies have dramatically modified treatment strategies in oncology since the early 2000’s, especially for treating digestive cancers. These new biotherapies such as anti-VEGF (bevacizumab) or anti-EGFR (cetuximab) monoclonal antibodies have given oncologists new opportunities to use innovative treatment schedules or combinations with cytotoxics. Consequently, significant improvements in response rates, with trends to longer progression-free survival and/or overall survival have been achieved in patients with metastatic colorectal cancer (mCRC). Panitumumab is a novel, 100% human, anti-EGFR1 (HER1) antibody that has been approved in late 2007 for use as monotherapy in mCRC patients resistant to standard chemotherapy, provided that their tumor express EGFR and display wild-type K-Ras status. Panitumumab has been recently further approved in combination with chemotherapy in mCRC patients. However, owing to the fact that its mechanism of action for targeting EGFR is similar to that of chimeric cetuximab, picturing the specificities in pharmacological and pharmacokinetic properties of this 100% human antibody could help the oncologists to better define their strategies at the bedside.
Keywords: Panitumumab, metastatic colorectal cancer, pharmacokinetics, monoclonal antibody
Current Topics in Medicinal Chemistry
Title:100% Human Monoclonal Antibodies in Oncology: Hype or Breakthrough?
Volume: 12 Issue: 15
Author(s): Stephan Benay, Raphaelle Fanciullino, Cedric Mercier, Athanassios Iliadis, Joseph Ciccolini and Bruno Lacarelle
Affiliation:
Keywords: Panitumumab, metastatic colorectal cancer, pharmacokinetics, monoclonal antibody
Abstract: Targeted therapies have dramatically modified treatment strategies in oncology since the early 2000’s, especially for treating digestive cancers. These new biotherapies such as anti-VEGF (bevacizumab) or anti-EGFR (cetuximab) monoclonal antibodies have given oncologists new opportunities to use innovative treatment schedules or combinations with cytotoxics. Consequently, significant improvements in response rates, with trends to longer progression-free survival and/or overall survival have been achieved in patients with metastatic colorectal cancer (mCRC). Panitumumab is a novel, 100% human, anti-EGFR1 (HER1) antibody that has been approved in late 2007 for use as monotherapy in mCRC patients resistant to standard chemotherapy, provided that their tumor express EGFR and display wild-type K-Ras status. Panitumumab has been recently further approved in combination with chemotherapy in mCRC patients. However, owing to the fact that its mechanism of action for targeting EGFR is similar to that of chimeric cetuximab, picturing the specificities in pharmacological and pharmacokinetic properties of this 100% human antibody could help the oncologists to better define their strategies at the bedside.
Export Options
About this article
Cite this article as:
Benay Stephan, Fanciullino Raphaelle, Mercier Cedric, Iliadis Athanassios, Ciccolini Joseph and Lacarelle Bruno, 100% Human Monoclonal Antibodies in Oncology: Hype or Breakthrough?, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531351
DOI https://dx.doi.org/10.2174/156802612803531351 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction
Reviews on Recent Clinical Trials Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Immune Stimulatory Strategies for the Prevention and Treatment of Asthma
Current Pharmaceutical Design Docosahexaenoic Acid (DHA) Sensitizes Brain Tumor Cells to Etoposide-Induced Apoptosis
Current Molecular Medicine Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Exploiting Novel Cell Cycle Targets in the Development of Anticancer Agents
Current Cancer Drug Targets Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets <i>In-silico</i> Studies and Wet-Lab Validation of Camptothecin Derivatives for Anti-Cancer Activity Against Liver (HepG2) and Lung (A549) Cancer Cell Lines
Current Topics in Medicinal Chemistry Cisplatin Analogues with an Increased Interaction with DNA: Prospects for Therapy
Current Pharmaceutical Design Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry